Oxford Asset Management’s Epizyme, Inc EPZM Stock Holding History

Oxford Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-36,453	Closed	-$376K	–	2200
2019 Q3	$376K	Sell	36,453 -76,268	-68%	-$962K	0.01%	1372
2019 Q2	$1.42M	Buy	112,721 +3,533	+3%	+$45.5K	0.03%	813
2019 Q1	$1.35M	Buy	+109,188	New	+$1.22M	0.03%	788
2017 Q3	–	Sell	-118,057	Closed	-$1.78M	–	1768
2017 Q2	$1.78M	Buy	+118,057	New	+$1.78M	0.04%	661
2016 Q3	–	Sell	-133,351	Closed	-$1.37M	–	891
2016 Q2	$1.37M	Buy	+133,351	New	+$1.49M	0.05%	431

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Oxford Asset Management's EPZM Position: Q4 2019 in Review

Oxford Asset Management sold out of Epizyme, Inc (EPZM) in Q4 2019, closing a stake of 36,453 shares — an estimated $376K sold.

Oxford Asset Management first reported a position in EPZM in Q2 2016 and held it in 5 quarters. The position peaked at $1.78M in Q2 2017. 136 funds tracked by Wall St. Rank hold EPZM as of Q4 2019.

Oxford Asset Management reported no remaining Epizyme, Inc position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 36,453 Epizyme, Inc shares in Q4 2019, an estimated $376K.
Oxford Asset Management first reported a position in Epizyme, Inc in Q2 2016 and held it in 5 quarters.
Oxford Asset Management's Epizyme, Inc position peaked at $1.78M in Q2 2017.
136 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.